Inventor · disambiguated record
Marc Van Dijk
Also filed as: VAN DIJK MARC · VAN DIJK MARC A
45 granted patents·20 pending applications·163 citations·filing 2015–2025
98Inventor score
Top patents by PatentIndex Score
65 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0297US10836830B2Antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Nov 17, 2020·12 cites·45 claims
- 0396US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0496US10639368B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 5, 2020·15 cites·32 claims
- 0596US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0696US10280226B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted May 7, 2019·17 cites·30 claims
- 0796US10155818B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2015·Granted Dec 18, 2018·17 cites·4 claims
- 0895US10912828B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·4 cites·36 claims
- 0995US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 1094US11242385B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Feb 8, 2022·8 cites·24 claims
- 1194US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 1293US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 1392US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 1492US10882908B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Jan 5, 2021·2 cites·36 claims
- 1592US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 1689US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 1789US10844119B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted Nov 24, 2020·3 cites·32 claims
- 1888US10800849B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Oct 13, 2020·2 cites·26 claims
- 1988US2025206818A1Anti-lag-3 antibodies and methods of use thereofAGENUS INC·Filed 2024·Application pending·0 cites
- 2087US10577426B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Mar 3, 2020·3 cites·21 claims
- 2186US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 2285US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 2385US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 2485US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 2584US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 2684US11447557B2Antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Sep 20, 2022·3 cites·46 claims
- 2784US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 2884US10829559B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Nov 10, 2020·1 cites·8 claims
- 2984US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3084US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3183US10675348B2Antibodies that bind human C6 and uses thereofREGENESANCE B V·Filed 2017·Granted Jun 9, 2020·2 cites·7 claims
- 3282US2023039577A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3382US2024181048A1Anti-tim-3 antibodies and methods of use thereofAGENUS INC·Filed 2023·Application pending·0 cites
- 3482US2025064923A1Antibodies that bind human c6 and uses thereofREGENESANCE B V·Filed 2024·Application pending·0 cites
- 3581US12194091B2Antibodies that bind human C6 and uses thereofREGENESANCE B V·Filed 2023·Granted Jan 14, 2025·0 cites·19 claims
- 3680US11359028B2Anti-OX40 antibodies and anti-GITR antibodiesAGENUS INC·Filed 2019·Granted Jun 14, 2022·1 cites·16 claims
- 3780US2023406946A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3880US2023399413A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3979US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 4079US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 4178US12492393B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Dec 9, 2025·0 cites·28 claims
- 4276US11718658B2T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereofMINK THERAPEUTICS INC·Filed 2020·Granted Aug 8, 2023·1 cites·21 claims
- 4376US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 4475US12187795B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Jan 7, 2025·0 cites·18 claims
- 4575US12011481B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Jun 18, 2024·0 cites·28 claims
- 4675US11897962B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 13, 2024·0 cites·11 claims
- 4775US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 4874US11993651B2Anti-lag-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 28, 2024·0 cites·15 claims
- 4974US11098117B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 24, 2021·0 cites·25 claims
- 5074US2022106581A1Anti-cd137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 65 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Marc Van Dijk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →